Search
Search Results
##search.searchResults.foundPlural##
-
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2291PDF: 1842HTML: 838 -
HODGKIN LYMPHOMA IN OLDER PATIENTS: AN ORPHAN DISEASE?
3005PDF: 1410HTML: 3723Untitled: 217Untitled: 227Untitled: 200 -
PROLIFERATION AND APOPTOSIS OF B-CELL LYMPHOMA CELLS UNDER TARGETED REGULATION OF FOXO3 BY miR-155 miR-155, FOXO3, B-cell lymphoma, proliferation, apoptosis, clinical characteristics
872PDF: 133HTML: 220 -
THE ROLE OF SLC22A4 IN ACUTE MYELOID LEUKEMIA
575PDF: 280HTML: 121 -
RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA MOLECULAR ALTERATIONS OCCURRING IN MM
1355PDF: 1119HTML: 249 -
TRANSCRIPTOME ANALYSIS OF BETA-CATENIN-RELATED GENES IN CD34+ HAEMATOPOIETIC STEM AND PROGENITOR CELLS FROM PATIENTS WITH AML Transcriptome analysis of beta-catenin-related genes in AML
1164PDF: 1217Suppl. Files: 586HTML: 98 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1513HTML: 643PDF: 880 -
RARE CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES
3919PDF: 1722HTML: 11837Figures Haase: 237 -
PROGNOSTIC FACTORS IN HODGKIN LYMPHOMA
3448PDF: 2042HTML: 7573 -
INTEREST IN DETERMINING THE CD34+ CD38- PHENOTYPE IN THE DIAGNOSIS AND PROGNOSIS OF ACUTE LEUKEMIA IN ABIDJAN – CÔTE D’IVOIRE
2064PDF: 778HTML: 723Table1: patient's characteristics: 175Table 2: profile of each patient: 198 -
PLASMACELL NEOPLASMS WITH SPREADING IN THE BLOOD AND TISSUES: EXTRAMEDULLARY MYELOMA DISEASE A RARE AGGRESSIVE FORM OF MULTIPLE MYELOMA (First of two parts) Extra Medullary Myeloma
2568HTML: 308PDF: 943 -
EPIDEMIOLOGICAL OVERVIEW OF HODGKIN LYMPHOMA ACROSS THE MEDITERRANEAN BASIN
3705PDF: 1267HTML: 5091Incidence age-standardized rates for HL across the Mediterranean basin: 233 -
NON-SECRETORY MYELOMA: READY FOR A NEW DEFINITION?
3359PDF: 1754HTML: 1167 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2667PDF: 843HTML: 5377 -
DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA
9333PDF: 6209HTML: 88092Fig.1b: 222Fig.1c: 222Fig.2a: 205Fig.2b: 204Fig.4: 226Fig.2c: 206Fig.3: 208Tab.1: 262Tab.2: 240Tab.3: 223Tab.4: 254Fig1a: 219 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1659PDF: 1105HTML: 478 -
PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1) Part 1- Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors and special populations
3719PDF: 2600HTML: 1626 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3796PDF: 936HTML: 6875 -
HEPARIN-BINDING PROTEIN AS A DIAGNOSTIC AND PROGNOSTIC MARKER OF INFECTIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS Heparin-binding protein in adult patients
3168PDF: 1084HTML: 272Suppl. Files: 529 -
SOLITARY PLASMACYTOMA
4189PDF: 2242HTML: 1402fIGURES 1,2: 252 -
Guest Editor: Pellegrino Musto REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA Multiple Myeloma High Risk Classificatio
2282PDF: 1667HTML: 563 -
IMMUNOGLOBULIN GENE REPERTOIRE IN CHRONIC LYMPHOCYTIC LEUKEMIA: INSIGHT INTO ANTIGEN SELECTION AND MICROENVIRONMENTAL INTERACTIONS
3193PDF: 925HTML: 7303Kost Fig1: 211Kost Fig 2: 198Kost Fig3: 204Kost Fig 4: 216Kost Fig5: 215Kost fig 6: 202 -
-
TYROSINE KINASE INHIBITORS AND PREGNANCY
3746PDF: 1721HTML: 2693 -
THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA
2564PDF: 821HTML: 1746 -
MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
4132PDF: 1577HTML: 9305Untitled: 306Untitled: 203Untitled: 190Untitled: 187Untitled: 205Untitled: 363 -
MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY
2853PDF: 1190HTML: 3311 -
“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”
4059PDF: 1097HTML: 3897Untitled: 187Cneo. Fig.1: 125Untitled: 120Untitled: 145Untitled: 154 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2932PDF: 1054HTML: 5642 -







